Research summary ·
Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review looked at past gout trials with random groups. A group called OMERACT has set core things to measure in gout trials. The team asked when and how often trials measured these core things. They also checked if trials reported all the results they gathered. They used 29 trials of urate-lowering drugs and 14 gout flare trials. The trials, from 2005 on, came from an earlier review.
What they found
In both trial types, the timing of tests differed a lot. In drug trials, blood urate and flares were most often checked each month. Tophus burden was most often checked less often than that. For blood urate, 24/29 trials reported all results they gathered. For activity limits, 0/2 trials did so. In flare trials, pain, tender joints and swollen joints were most often checked monthly. For pain, 13/14 flare trials reported all the results. For tender joints, 3/8 trials did so.
What it means for patients
The authors say there is wide variation in when core things are measured. They say reporting of the collected results is not consistent. They see this work as a base for agreeing on standard times. The goal is set times and gaps for measuring gout core domains.
Why it is not certain yet
This review looked at how trials were run, not how well drugs worked. Some counts were small, such as 2 trials for activity limits. The abstract does not give the agreed time points yet. A review can only be as good as the studies in it.
Source
Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials.
PubMed · PMID 42641197We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Gout publications